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OBJECTIVES: Analyze the economic impact of the A-H1N1 flu epidemic for the
health sector in Mexico in the 2009-2010 period, that resulted in the first pandemic
of the XXI century, in order to plan the resources provision and review policies
aimed to deal with similar future events. METHODS: The exercise had several
stages. First, a collect of the expenditures incurred by the health sector at federal
level between April 2009 and August 2010 was made. Second, the collected infor-
mation was classified into two areas of analysis: a) health care expenditures, and b)
additional costs from purchasing and application of vaccines, medical equipment,
drugs and health products, federal support to states, and national media cam-
paigns. Third, health care expenditure and expenditure by area of analysis was
estimated by aggregating all costs. RESULTS: Total federal expenditure related to
addressing the epidemic in the health sector was estimated in USD$ 733.3 million,
32% linked to health care and 93.7% exercised in 2009, corresponding to 11.2% of the
total health expenditure budget for this year. This expenditure involved medical
attention of 368 thousands patients, purchasing and application of 6.8 million of
anti-flu seasonal vaccines and 30 million of anti-AH1N1flu vaccines. For health
care, a total expenditure of USD$ 216.7 million was estimated, 80% exercised in
2009, that involves medical attention of 330 thousand patients. A total expenditure
of USD$ 516.3 million was estimated for additional costs, more than 99% exercised
in 2009. The main component of this area was the purchase and application of
A-H1N1 flu vaccine (USD$ 228.8 million). CONCLUSIONS: The exercise allows
knowing the mayor spending areas and generates evidence to strengthen the fi-
nancial and operational planning processes to face similar health events, such as
the need to anticipate resources and contingency funds in addition to administra-
tive and operational processes.
PIN3
PURSUING FINANCIAL SUSTAINABILITY TO FULFILL THE MILLENIUM
DEVELOPMENT GOAL SIX IN A FRAGMENTED SYSTEM. THE EXPERIENCE OF
THE UNIVERSAL ACCESS TO ANTIRETROVIRAL DRUGS IN MÉXICO 2007-2009
Rivera-Peña G, Rios-Arenas D, Gutierrez-Delgado C
Economic Analysis Unit, México, D.F., México
OBJECTIVES: To calculate the average annual cost per ART in IMSS, ISSSTE and
MoH. To analyze the financial requirements for the provision of ART through the
Universal Access Program to Antiretroviral Drugs (PAUMA) lead for the MoH and its
implications for drug procurement policies at national level in the short and me-
dium terms.METHODS:We obtained data about patients under ART in 2007 for the
three main institutions mentioned and in 2009 only for MoH. Information was
analyzed to identify ART prescriptions according to official recommendations. Av-
erage annual cost of ART per patient and institution was estimated for 2007 and
2009. Projections of the financial requirements to ensure the provision of ART
through the PAUMA for the period 2010-2017 were estimated. Analysis was devel-
oped in STATA 9.2. RESULTS: In 2007 average annual cost of ART for the three main
institutions was MXP$64,800; per institution were as follow: ISSSTE MXP$74,300;
IMSS MXP$67,600 and MoH MXP$61,600. Information for the MoH indicates that
average annual cost of ART decreased between 2007 and 2009 by around 10.2% (in
2009 was MXP$55,300). First 20 ART options are prescribed to 80% of the patients
and represent around 73% of the total costs in 2009. Projections for PAUMA in the
period 2010-2017 indicate that on average annually 7,000 new patients require ART
and 5,000 deaths will occurred. Assuming new cases, deaths and prices of antiret-
roviral drugs remain constant the average annual increase in financial require-
ments for PAUMA to ensure ART in the period studied will be 5.6%. CONCLUSIONS:
Results generate evidence to strengthen the decision making, monitoring, contain-
ment costs, and purchase of antiretroviral drugs processes. It also provides infor-
mation to allow policy makers optimize the use of limited public resources to
support the demand for ART through the financial armor that contributes to main-
tain universal coverage, allowing the fulfillment of Goal 6 of the Millennium Devel-
opment Goals.
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ECONOMIC IMPACT OF COMMUNITY ACQUIRED PNEUMONIA
HOSPITALIZATIONS IN ADULTS IN SIX COUNTRIES IN LATIN AMERICA
Rosado-Buzzo A1, Garcia-Mollinedo L1, Camacho-Cordero L1, Roberts CS2,
Mould-Quevedo JF2, Trejo-Martinez A1, Luna-Casas G1
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OBJECTIVES:To estimate the economic impact of community acquired pneumonia
(CAP) in adults over 50 years of age in Argentina, Brazil, Chile, Colombia, Mexico,
and Venezuela.METHODS: Local data sources were used to estimate the number of
cases of hospitalized pneumonia cases from ICD-9 codes in the year 2009 in adults
50 years of age. CAP episodes were estimated from pneumonia proportionally by
age based on prior publications that compared ICD-9 coded hospitalizations to
confirmed CAP by chart review. Resource use was estimated from treatment guide-
lines and expert opinion and multiplied by local unit costs to derive total costs.
Indirect costs to patients and caregivers were estimated by average wages times
participation rate by age. Mortality cost was estimated by discounted life expec-
tancy times wage rates and participation rates by age group. Costs were converted
to USD by exchange rates to facilitate comparison. RESULTS: The average cost of
CAP hospitalizations in adults was (USD): Argentina$32,241; Brazil$29,457;
Chile$26,936; Colombia$23,656; Mexico$21,018; Venezuela$22,536. In adults
65 years old, indirect costs comprised 1.5% of cost associated with hospitaliza-
tions (range: 0.2% - 2.5%) and mortality costs comprised 16% (range: 3% - 24%). In
adults 65 direct costs were over 95% of episode costs. The total cost of CAP hos-
pitalizations in adults was (USD$Mil): Argentina$697; Brazil$3,624; Chile$445;
Colombia$347; Mexico$941; Venezuela$387. As a proportion of the total pop-
ulation, CAP hospitalizations cost approximately $74 per person 50 years old per
year (range $42-$108) and $148 per person over 65 per year (range $95-$235).
CONCLUSIONS: CAP hospitalizations represent a significant economic burden in
adults across Latin America countries. Nearly one quarter of the cost burden
among adults65 includes indirect costs, while the economic burden among older
patients is driven by direct costs and high incidence.
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EVALUACION COSTO-EFECTIVIDAD DEL USO DE LINEZOLID EN EL
TRATAMIENTO DE NEUMONIAS NOSOCOMIALES EN MÉXICO
Vargas-Valencia JJ1, Sotelo-Guzmán M1, Díaz-Ponce H2, Galindo-Suárez RM2,
Muciño-Ortega E2, Mould-Quevedo JF3
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OBJECTIVOS: La neumonía nosocomial (NN) es la segunda causa más frecuente de
infección intrahospitalaria, la infección más frecuentemente adquirida en la uni-
dad de cuidados intensivos (UCI) y la primera causa de mortalidad por infecciones
intrahospitalarias. El objetivo de esta investigación fue estimar el costo-efectividad
del uso de linezolid en el tratamiento de la NN en comparación con el uso de
vancomicina y teicoplanina, desde la perspectiva del Instituto Mexicano del Seguro
Social (IMSS). METODOLOGÍAS: Se construyó un árbol de decisiones que compara
el uso de linezolid inyectable, seguido por linezolid oral (600mg dos veces/día),
vancomicina inyectable (1000mg dos veces/día) y teicoplanina inyectable (400mg
dos veces el primer día, días subsecuentes: 400mg) en el tratamiento de NN (hori-
zonte temporal: 38 días). Se evalúan la tasa de éxito microbiológico, los días de
estancia hospitalaria (en piso y UCI) y los costos médicos directos. Se realizó una
revisión de literatura para extraer la tasa de respuesta. La relación de insumos
(laboratorios, consultas y medicamentos) y procedimientos, así como el manejo
hospitalario se extrajó de la literatura y se complementó con opinión de expertos.
Los costos corresponden al IMSS para el año 2010. Se realizó análisis de sensibilidad
probabilístico. RESULTADOS: La tasa de éxito microbiológico del tratamiento con
linezolid fue de 64%, 59.5% con vancomicina (p0.336) y 44.1% con teicoplanina
(p0.001). Esto se refleja en una menor estancia en UCI, con 17.4 días para linezolid,
21.26 días con vancomicina y 21.82 días para teicoplanina. El costo total de trata-
miento con linezolid fue $777,873.14, siendo menor respecto del de vancomicina
($865,186.96) y teicoplanina ($931,983.09). Las curvas de aceptabilidad muestran
que linezolid es costo ahorrador con respecto a vancomicina o teicoplanina.
CONCLUSIONES: En el tratamiento de las NN en el contexto del IMSS, linezolid
presenta dominacia débil sobre vancomicina y dominancia absoluta sobre teico-
planina.
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COST-EFFECTIVENESS ANALYSIS OF ANTI-PNEUMOCOCCAL VACCINES VERSUS
NO VACCINATION IN EL SALVADOR
Dueñas MDL1, Lutz M2, Morales G2, Strutton DR3, Roberts C4, Cuesta G2, Farkouh RA3
1Hospital Centro Pediátrico, San Salvador, El Salvador, 2Pfizer S.A., La Aurora, Heredia, Costa
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OBJECTIVES: In 2009, it was estimated that there were 12.000 to 28.000 deaths in
Latin America related to Streptococcus pneumonia infections in pediatric popula-
tion under 5 years old. Currently, in El Salvador, Prevenar 7 (PCV-7) is the anti-
pneumococcal vaccine used. The aim of this study was to estimate the cost-effec-
tiveness and cost-utility of immunization strategies based on pneumococcal
conjugated vaccines (PCVs) in El Salvador, from an institutional perspective.
METHODS:A decision tree model was used to asses economic and health impact of
PCVs in children under 2 years old. The alternatives compared were: no vaccination
(comparator), PCV-7, PCV-10 and PCV-13. The effectiveness measures were: child
illness avoided, life years gained (LYs) and quality-adjusted life years (QALYs)
gained. Effectiveness and utilities were obtained from literature. Local costs (ex-
pressed in 2009 $US) and epidemiology (data from 2009) were obtained from El
Salvador=s Ministry of Health database. The model included vaccine dosage sched-
ules approved in WHO prequalification and/or El Salvador MoH calendar at the
time of data collection (dec-2010). Univariate sensitivity analysis was performed.
The time horizon was one year and the discount rate was 3%. RESULTS: Results
show that immunization is cost-saving against no-vaccination. PCV-13 gained the
highest number of QALYs (898) against PCV-10 (637) and PCV-7 (460). PCV-13 pre-
vented 359 illnesses and gained 998 LYs. PCV-10 and PCV-7 prevented 257 and 228
illnesses and gained 707 and 511 LY=s, respectively. These results were robust to
variations in herd immunity and impact adjustments of PCV10 immunogenicity.
CONCLUSIONS: In El Salvador, immunization strategies based on 7, 10 and 13-
valent PCV=s would be cost-saving interventions. Health outcomes and savings of
PCV-13 are greater than those estimated for 7 and 10-valent PCV=s.
PIN8
EVALUACION ECONOMICA DE LA EXTENSION DE PROFILAXIS CONTRA CMV DE
100 A 200 DIAS EN RECEPTORES DE TRASPLANTE RENAL CON ALTO RIESGO
(D / R)
Morales Buenrostro LE
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, México, DF, México
OBJECTIVOS: Traducir los beneficios clínicos de extender el período de profilaxis
con Valganciclovir de 100 a 200 días en un análisis de costo-efectividad de largo
plazo en la etapa postrasplante en pacientes con alto riesgo de enfermedad por
Citomegalovirus (CMV) (D / R). METODOLOGÍAS: Se utilizó un Modelo Markov
para simular los costos de los diferentes estadios de la enfermedad. Los horizontes
temporales evaluados son: menor a un año, un año, cinco años y diez años. La
población modelada son pacientes receptores de trasplante renal (RTR) con alto
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riesgo de contraer CMV. Se compararon dos esquemas de profilaxis con Valganci-
clovir 100 vs. 200 días. Tasa de descuento para un horizonte temporal mayor a 1
año: 3% (Aplica para costos y utilidades). Los costos médicos directos asociados con
los diferentes estadios, se obtuvieron del listado de costos unitarios para el IMSS,
publicados en el Diario Oficial de la Federación 2010 y el portal de compras guber-
namentales Compranet. RESULTADOS: En el caso de receptores con alto riesgo,
extender profilaxis con Valganciclovir a 200 días, muestra una notable mejoría en
los resultados de salud y una baja en los costos asociados a las complicaciones por
enfermedad del CMV. De una cohorte de 100 pacientes, dentro de los 2 siguientes
años, se evitará la infección por CMV en 18 pacientes, adicional a esto se redujeron
en un 53% el riesgo de rechazo agudo, un 28% la pérdida de la función del injerto y
un 23% la probabilidad de muerte. CONCLUSIONES: La reducción y/o retraso de
infecciones por CMV en RTR resultará en una reducción de los costos en el largo
plazo. En el corto plazo se observarán menos complicaciones por la enfermedad del
CMV en pacientes inmunosuprimidos y en el largo plazo se reducirá la incidencia
de fallas del injerto y la probabilidad de muerte.
PIN10
EXCHANGE RATE OR POWER PURCHASE PARITY FOR ECONOMIC EVALUATION:
ESTIMATING THE COSTS OF ROTAVIRUS VACCINATION IN A SIX-YEAR PERIOD
CONSIDERING DATA FROM MEXICAN CHILDREN
Granados-Garcia V1, Salinas-Escudero G2, Martinez-Valverde S2
1National Institute of México for Social Security (IMSS), México, D.F., México, 2Hospital Infantil
de México Federico Gómez, Secretaría de Salud, México, D.F., México
OBJECTIVES: To undertake a comparison of cost effectiveness estimates in differ-
ent currencies for the program of vaccination to prevent rotavirus diarrhea for
children less than five years of age. METHODS: Cost effectiveness estimates were
conducted considering yearly cohorts of children from 0 to 5 years of age for a
period of 6 years (2001-2006). We used two alternatives for presenting the values of
costs when transforming the Mexican pesos to dollars. In one alternative we pres-
ent the costs and cost effectiveness results in US dollars (with yearly average ex-
change rates) and the second was the purchase power-parity factors. We compare
the results obtained considering the exchange rates and PPP factors for each one
year. Costs data and cost effectiveness ratios were expressed in 2006 prices.
RESULTS: We found that the cost per DALY in base case estimate was estimated at
US$ 3640 per DALY ranging between US$ 2692 and 4502. The variations of the
estimates using PPP were between 48-59% larger than estimates using US dollars.
CONCLUSIONS: Estimates of cost effectiveness using US dollars or PPP did not
change the conclusion which suggest that the vaccine is cost effective by using of
the rule of three times GDP per capita of the country as a threshold of the cost per
DALY in low and middle-income countries.
PIN11
EVALUACION ECONOMICA DE LAS VACUNAS CONJUGADAS DE PNEUMOCOCO
PARA PERU
Tirado Caballero JC1, Navarro A2, Castrejon MM3, Gomez JA4
1Complejo Hospitalario San Pablo, Lima, Peru, 2GlaxoSmithKline, Lima, Peru, 3GlaxoSmithKline,
Panama City, Panama, 4GlaxoSmithKline, Victoria, Buenos Aires, Argentina
OBJECTIVOS: Evaluar los beneficios potenciales de la vacuna conjugada 10-valente
de neumococo & proteína D de Haemophilus influenzae no tipificable (HiNT) (PHiD-
CV) y la vacuna conjugada 13 valente de neumococo (PCV-13) para Perú.
METODOLOGÍAS: Se utilizó un modelo Markov de cohorte. El modelo simula el
impacto de la enfermedad por neumococo y HiNT (enfermedad invasiva (EI), neu-
monía adquirida en comunidad (NAC), y otitis media aguda (OMA)) en una cohorte
peruana seguida toda la vida. La epidemiología, el manejo de enfermedad y los
costos utilizados fueron específicos de Perú. El escenario base incluyó asunciones
mínimas sobre las tasas de infección por HiNT. Se utilizó un esquema de vacu-
nación 31, una cobertura del 95% y precios por dosis de la Organización Pana-
mericana de la Salud (PHiD-CV: 14,85 dólares, y PCV13: 20,00 dólares). Se presentan
resultados de años de vida ganados ajustados por calidad (AVACs) y costos utili-
zando un descuento del 3,5%, desde la perspectiva del pagador. RESULTADOS: El
modelo estimó resultados comparables sobre mortalidad por EI y NAC para las
dos vacunas, en el escenario base. Predice que las vacunas reducirían 51,5
muertes (PCV13) y 50,0 muertes (PHiD-CV) por cada 100,000 niños vacunados.
PHiD-CV prevendría 364 más miringotomías y 4.403 más OMAs cada 100,000
niños vacunados versus PCV-13. Los costos médicos evitados (sin descuento)
por EI y NAC prevenidas, son similares para las dos vacunas. En cambio,
PHiD-CV ahorraría 1,9 veces más costos médicos por OMAs que PCV13. Ambas
vacunas son costo efectivas, pero PHiD-CV generaría más AVACs ganados (378
AVACs adicionales) y sería costo ahorrativa (requiere 10 millones de dólares
menos) comparado con PCV13. CONCLUSIONES: Ambas vacunas reducirían sig-
nificativamente la enfermedad neumocóccica invasiva y la NAC siendo PHiD-CV la
que generaría más AVACs ganados siendo costo ahorrativa con respecto a PCV-13,
al presentar mayores efectos sobre OMA.
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ANALISIS DE COSTO-EFECTIVIDAD DEL USO DE PROTEINA C ACTIVADA (PCA)
EN ENFERMOS CON SEPSIS GRAVE Y CHOQUE SÉPTICO EN LA UNIDAD DE
CUIDADOS INTENSIVOS DEL HOSPITAL REGIONAL 1° DE OCTUBRE DEL ISSSTE
Villagómez A1, García S2, Carlos F3, Lemus A4
1Hospital Regional 1° de Octubre del Instituto de Seguridad y Servicios Sociales de los
Trabajadores del Estado, México, D.F., México, 2Centro Médico Nacional 20 de Noviembre del
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, México, D.F., México,
3R A C Salud Consultores, S.A. de C.V., México, D.F., México, 4Universidad Anáhuac, México,
D.F., México
OBJECTIVOS: La sepsis y el choque séptico representan una de las principales
causas mundiales de morbilidad y mortalidad, generando un impacto
económico considerable. El objetivo fue evaluar los costos y el beneficio por
reducción de mortalidad asociados con el uso de proteína C activada (PCA) en
pacientes con sepsis grave o choque séptico (SGoCS) desde la perspectiva del
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
(ISSSTE).METODOLOGÍAS: Se realizó un estudio transversal, comparativo, abierto,
analítico y retrospectivo con 200 pacientes adultos con SGoCS atendidos en la
Unidad de Cuidados Intensivos (UCI) del Hospital Regional 1° de Octubre del
ISSSTE. La inclusión fue no aleatoria y consecutiva de enero de 2007 a diciembre de
2009. El tratamiento estándar se otorgó conforme a guías internacionales. PCA fue
administrada en forma intravenosa (24 g/kg/h) con duración total de 96 horas. Se
analizó la mortalidad a 28 días de inicio del tratamiento en cada grupo. Utilizando
las proyecciones del Consejo Nacional de Población y el factor de Quartin se estimó
la expectativa de vida restante en los sobrevivientes (tasa de descuento5%). Se
contemplaron los costos de adquisición de PCA y estancia hospitalaria en UCI.
Todos los costos se expresan en pesos mexicanos (MXN) 2010. RESULTADOS: Am-
bos grupos eran comparables: edad media 60 años, 57% mujeres, puntuación
APACHE II (23.3 Vs. 24.0 en PCA y tratamiento estándar), número de órganos con
disfunción (3.8 y 3.6 en PCA y tratamiento estándar). Menos muertes ocurrieron en
el grupo PCA (52 Vs. 57): riesgo relativo0.91 (IC95%0.71-1.18). El costo por salvar
una vida adicional con PCA fue $1,159,591. Los costos por año de vida ganado y por
año de vida ajustado por calidad (AVAC) adicional con PCA fueron $163,324 y
$272,207 respectivamente. CONCLUSIONES: El uso de PCA en pacientes con SGoCS
constituye una estrategia costo-efectiva.
Mental Health – Clinical Outcomes Studies
PMH1
COMPARING THE EFFECTIVENESS OF PALIPERIDONE PALMITATE VERSUS
OLANZAPINE PAMOATE FOR RELAPSE PREVENTION IN SCHIZOPHRENIA: POST
HOC INDIRECT ANALYSIS USING PUBLISHED PLACEBO-CONTROLLED STUDIES
Einarson T
University of Toronto, Toronto, ON, Canada
OBJECTIVES: Presently, no published studies compare head-to-head long-acting
injectable (LAI) antipsychotics paliperidone palmitate (PP) and olanzapine pamoate
(OLANZ) for schizophrenia; therefore, this indirect analysis was undertaken to
examine long-term relapse rates. METHODS: A priori criteria included: Patients:
adults 18 with DSM diagnosis of schizophrenia, non-suicidal outpatients with
stable disease, taking minimal other medications; Designs: placebo-controlled,
double-blind, stabilized on LAIs and treated long-term; Outcome was relapse rate;
Definitions: must have defined relapse and stabilization. We compared between
LAI and placebo within studies using risk ratios (RR) for relapse rates derived from
Kaplan-Meier curves. Bucher’s method was used to compare indirectly between
LAIs.RESULTS:We identified two similar trials, one for each LAI. At randomization,
patients had similar meanSD age (PP39.111.1, OLANZ38.911.2), BMI
(PP27.35.8, OLANZ26.95.0), and PANSS-Total scores (PP52.611.8,
OLANZ55.815.2). Research designs and definitions were also comparable. For a
valid comparison, outcomes at 24 weeks were analyzed. In the PP trial (Hough; Trial
PSY-3001), 206 patients received PP (50 or 100 mg Eq, which could be adjusted to 25,
50 or 100 mg Eq; average dose: 82.8 mg/4 weeks; 1.18 daily-defined-doses[DDDs]),
204 received placebo. In the OLANZ trial (Kane; Trial HGKA), 599 patients were
randomized to receive OLANZ (150 mg/2 weeks, 405 mg/4 weeks, or 300 mg/2
weeks; average dose: 426 mg/4 weeks; 1.52 DDDs) and 144 received pseudo-placebo
(45 mg/month), a very low clinically sub-therapeutic dose assumed to be compa-
rable to placebo. PP had significantly fewer relapses than placebo (RR0.31; CI95%:
0.22-0.44) as did OLANZ (RR0.33, CI95%:0.24-0.46). The indirect RR of OLANZ ver-
sus PP was 1.06 (CI95%:0.65-1.72). However, the monthly dose was 29% higher for
OLANZ (426 mg, 1.52 DDDs) than for PP (82.8 mg, 1.18 DDDs). CONCLUSIONS: No
differences were found in 6-month relapse rates between LAIs; however, OLANZ
required higher DDDs. These findings could impact outcomes from cost-effective-
ness analyses.
Mental Health – Cost Studies
PMH2
THE COST-EFFECTIVENESS OF PALIPERIDONE PALMITATE COMPARED TO
OLANZAPINE PAMOATE IN THE TREATMENT OF SCHIZOPHRENIA IN SWEDEN
Pudas H1, Hemels M2, Mehnert A3, Druais S4, Martin M4
1Janssen-Cilag Oy, Espoo, Finland, 2Janssen-Cilag AS, Birkerod, Denmark, 3Janssen
Pharmaceutica NV, Beerse, Belgium, 4i3 Innovus, Uxbridge, Middlesex, UK
OBJECTIVES: To compare from the Swedish societal perspective the cost-effective-
ness of paliperidone palmitate administered monthly (75mg eq every month) (PP)
with olanzapine pamoate (150mg every 2 weeks or 300mg every 4 weeks) (OP).
METHODS: A Markov decision analytic model was developed simulating a cohort
of stable schizophrenia patients transitioning monthly through different health
states over a lifetime (55 years). Probability of relapse, level of adherence, side-
effects (extrapyramidal symptoms, tardive dyskinesia, weight gain and diabetes)
and treatment discontinuation (switch) were derived from long-term observational
data. Productivity losses were included in the analysis. Costs were expressed in
2011 Swedish Kronor (1 SEK	 0,159 US dollar) with costs and benefits discounted at
3%. Drug costs were derived from the Swedish Pharmaceutical Benefits agency
(TLV). Primary cost-effectiveness measures were the cost / QALY gained and cost /
relapse avoided. RESULTS: Compared to OP, PP is dominant: an increased effec-
tiveness (additional QALYs 2.097) and fewer relapses (0.395) at reduced costs (SEK
26 719) over a lifetime horizon. Results were robust when tested in 33 deterministic
(DSA) and probabilistic sensitivity analyses (PSA) using 12 parameters with pre-
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